Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury
The Walter Reed Army Institute of Research has commenced a study assessing the effectiveness of Nyrada's (ASX:NYR) NYR-BI03 in traumatic brain injury, according to a Tuesday filing with the Australian
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program
Drug developer Nyrada (ASX:NYR) posted its quarterly activities report for the period ending March 31, which shows the company completed a stroke study in its brain injury program NYR-BI03, according
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate
Nyrada (ASX:NYR) has begun its good laboratory practice preclinical study to test NYR-BI03, the company's drug candidate for treating brain injury, according to an Australian bourse filing on Thursday
Nyrada Raises AU$1.8 Million via Placement
Drug development firm Nyrada (ASX:NYR) raised a total of AU$1.755 million of new equity capital, before costs, from new and existing professional and sophisticated investors, according to a Wednesday
Significant Results for Nyrada's Brain Injury Treatment
Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results for using NYR-B103 to treat brain injuries.Paul Sanger: I'm Paul Sanger for the Finance News Network, and today I'm talking to Nyrada Inc (A
Nyrada NYR-BI03 Trial Success Heralds Breakthrough in Stroke and Brain Injury Treatment
Drug discovery and development company Nyrada (ASX: NYR) has announced positive results from a pre-clinical study evaluating lead candidate NYR-BI03 in the prevention of secondary brain injury.
Stocks of the Hour: Nyrada Inc, Bastion Minerals, Global Oil & Gas
To register for Friday's webinar click here.Nyrada Inc (ASX:NYR), a drug discovery and development company specialising in novel small molecule therapeutics to treat neurological and cardiovascular di
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%
Nyrada (ASX:NYR) secured a rebate worth AU$3.54 million from the Australian government's research and development tax incentive scheme for the fiscal year ended June 30, the drug development firm said
Australian Shares Flat as June Unemployment Rate Remains at 3.5%
Australian shares traded flat with a positive bias on Thursday as the country's June unemployment rate was unchanged. The S&P/ASX 200 Index inched up 1.30 points to 7,325.00. Australian unemployment r
Nyrada Halves Director Fees; Shares Jump 37%
Nyrada (ASX:NYR) said its board voluntarily agreed to halve the fees of its directors until further notice, effective Thursday, according to a same-day news release. The drug developer expects the mov
No Data